<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849990</url>
  </required_header>
  <id_info>
    <org_study_id>9628</org_study_id>
    <secondary_id>NCI-2016-01027</secondary_id>
    <secondary_id>9628</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1716056</secondary_id>
    <nct_id>NCT02849990</nct_id>
  </id_info>
  <brief_title>A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy</brief_title>
  <official_title>A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix,
      and indomethacin work in treating patients with prostate cancer that has spread from where it
      started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of
      tumor cells. Hormone therapy using apalutamide, abiraterone acetate, prednisone, degarelix,
      and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes
      and/or blocking the use of androgen by the tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. The rate of the pathologic complete response (pCR) (i.e. no evidence of residual tumor) as
      assessed on prostatectomy specimens following 3-months (12 weeks) of neoadjuvant apalutamide,
      abiraterone acetate, degarelix and indomethacin.

      SECONDARY OBJECTIVES:

      I. To determine the negative margin rate as assessed on prostatectomy specimens following
      3-months (12 weeks) of neoadjuvant apalutamide, abiraterone acetate, degarelix and
      indomethacin.

      II. To determine the rate of near pCR (i.e. =&lt; 5 mm of residual tumor) as assessed on
      prostatectomy specimens following 3-months (12 weeks) of neoadjuvant apalutamide, abiraterone
      acetate, degarelix and indomethacin.

      III. To determine the rate of pathologic T3 disease as assessed on prostatectomy specimens
      following 3-months (12 weeks) of neoadjuvant apalutamide, abiraterone acetate, degarelix and
      indomethacin.

      IV. To determine the rate of nodal metastases as assessed on surgical lymph node specimens
      following 3-months (12 weeks) of neoadjuvant apalutamide, abiraterone acetate, degarelix and
      indomethacin.

      V. To determine the apoptotic index (i.e. percentage of tumor cells undergoing apoptosis) as
      determined by cleaved caspase-3 immunohistochemistry following 3-months (12 weeks) of
      neoadjuvant apalutamide, abiraterone acetate, degarelix and indomethacin.

      VI. To determine the proportion of men who receive adjuvant radiation therapy within 1-year
      of prostatectomy.

      VII. To determine the biochemical (i.e. prostate-specific antigen [PSA]) progression free
      survival estimate two years after the last patient has accrued (i.e. confirmed PSA
      post-radical prostatectomy &gt;= 0.2 ng/mL).

      VIII. To determine the overall survival estimate two years after the last patient has
      accrued.

      IX. Safety as assessed by the incidence and severity of adverse events and serious adverse
      events graded according to the National Cancer Institute - Common Terminology Criteria for
      Adverse Events (CTCAE) version 4.0.

      X. Exploratory biomarker assessment.

      OUTLINE:

      Patients receive apalutamide and abiraterone acetate orally (PO) daily, prednisone PO twice
      per day (BID) and indomethacin PO three times per day (TID). Patients also receive degarelix
      subcutaneously (SC) on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12
      weeks in the absence of disease progression or unacceptable toxicity. Patients undergo
      prostatectomy on day 85.

      After completion of study treatment, patients are followed up at 28, 113, 450 and 815 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">September 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate as Assessed From Prostatectomy Specimens Following Neoadjuvant Treatment</measure>
    <time_frame>At 3 months</time_frame>
    <description>Pathologic complete response is defined as no evidence of cancer on fully submitted prostatectomy specimens using standard surgical pathology assessments (i.e. H&amp;E assessment will be used for the purpose of defining pathologic complete response per protocol) at 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apoptotic Index (i.e. Percentage of Tumor Cells Undergoing Apoptosis)</measure>
    <time_frame>At 3 months</time_frame>
    <description>Will be determined by cleaved caspase-3 immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Negative Margin After 3 Months of Treatment</measure>
    <time_frame>At 3 months</time_frame>
    <description>The absence of tumor cells at the prostate margin will be assessed using standard pathological practices on prostatectomy specimens (i.e. after 3 months of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be estimated using Kaplan-Meier methods and 95% CI will be estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Near Pathologic Complete Response After 3 Months of Treatment</measure>
    <time_frame>At 3 months</time_frame>
    <description>The near pathologic complete response will be defined as =&lt; 5 mm of residual tumor as assessed on prostatectomy specimens after 3 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With no Nodal Metastases After 3 Months of Treatment.</measure>
    <time_frame>At 3 months</time_frame>
    <description>The presence of tumor cells within surgically excised lymph nodes will be assessed after 3 months of treament.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Pathologic T3 Disease After 3 Months of Treatment.</measure>
    <time_frame>At 3 months</time_frame>
    <description>The presence of T3 disease (e.g. extraprostatic tumor not invading adjacent structures) will be determine from the prostatectomy specimen after 3 months of treament.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Biochemical (i.e. Prostate-specific Antigen) Progression-free Survival (PFS) Estimate</measure>
    <time_frame>At 2 years</time_frame>
    <description>Prostate-specific antigen progression (i.e. biochemical failure) will be defined per the American Urological Association guidelines (i.e. confirmed prostate-specific antigen post-radical prostatectomy &gt;= 0.2 ng/mL). Will be estimated using Kaplan-Meier methods and 95% CI will be estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Men Who Receive Adjuvant Radiation Therapy</measure>
    <time_frame>Up to 1 year post prostatectomy</time_frame>
    <description>Patients that received radiation following prostatetomy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Stage III Prostate Adenocarcinoma AJCC v7</condition>
  <condition>Stage III Prostate Cancer AJCC v7</condition>
  <condition>Stage IV Prostate Adenocarcinoma AJCC v7</condition>
  <condition>Stage IV Prostate Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (neoadjuvant chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy)</arm_group_label>
    <other_name>ARN 509</other_name>
    <other_name>ARN-509</other_name>
    <other_name>ARN509</other_name>
    <other_name>JNJ 56021927</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy)</arm_group_label>
    <other_name>FE200486</other_name>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy)</arm_group_label>
    <other_name>Indocin</other_name>
    <other_name>Indometacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (neoadjuvant chemotherapy)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Documented histologically confirmed adenocarcinoma of the prostate

          -  Willing to undergo prostatectomy as primary treatment for localized prostate cancer

          -  High risk prostate cancer (per National Comprehensive Cancer Network [NCCN] criteria):
             Gleason score 8-10 or T3a or PSA &gt; 20 ng/mL or very-high risk prostate cancer (per
             NCCN criteria): T3b-T4

          -  Serum testosterone &gt;= 150 ng/dL

          -  Able to swallow the study drugs whole

          -  Willing to take abiraterone acetate on an empty stomach (no food should be consumed at
             least two hours before and for one hour after dosing)

          -  Agrees to use a condom (even men with vasectomies) and another effective method of
             birth control if he is having sex with a woman of childbearing potential or agrees to
             use a condom if he is having sex with a woman who is pregnant while on study drug and
             for 3 months following the last dose of study drug; must also agree not to donate
             sperm during the study and for 3 months after receiving the last dose of study drug

          -  Medications known to lower the seizure threshold (see list under prohibited meds) must
             be discontinued or substituted at least 4 weeks prior to study entry

        Exclusion Criteria:

          -  Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation
             therapy, brachytherapy)

          -  Prior use of apalutamide, abiraterone acetate or degarelix

          -  Prior or ongoing systemic therapy for prostate cancer including, but not limited to:

               -  Hormonal therapy (for example [e.g.] leuprolide, goserelin, triptorelin,
                  degarelix)

               -  Cytochrome P450 (CYP)-17 inhibitors (e.g. ketoconazole)

               -  Antiandrogens (e.g. bicalutamide, nilutamide)

               -  Second generation antiandrogens (e.g. enzalutamide, apalutamide)

               -  Immunotherapy (e.g. sipuleucel-T, ipilimumab)

               -  Chemotherapy (e.g. docetaxel, cabazitaxel)

          -  Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety or provision of informed consent to participate in this study

          -  Any psychological, familial, sociological, or geographical condition that could
             potentially interfere with compliance with the study protocol and follow-up schedule

          -  Absolute neutrophil count [ANC] &lt; 1500/mm^3

          -  Platelet count &lt; 100,000/mm^3

          -  Hemoglobin &lt; 9 g/dL

          -  Total bilirubin &gt; 1.5 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;= 2.5 x ULN; Note:
             in subjects with Gilbert's syndrome, if total bilirubin is &gt; 1.5 x ULN, measure direct
             and indirect bilirubin and if direct bilirubin is =&lt; 1.5 x ULN, subject may be
             eligible

          -  Abnormal kidney function (glomerular filtration rate GFR &lt; 45 mL/min)

          -  Serum albumin &lt; 3 g/dL

          -  Serum potassium &lt; 3.5 mmol/L

          -  Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1
             year to randomization, brain arteriovenous malformation, schwannoma, meningioma, or
             other benign central nervous system [CNS] or meningeal disease which may require
             treatment with surgery or radiation therapy)

          -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart
             failure, arterial or venous thromboembolic events (eg, pulmonary embolism,
             cerebrovascular accident including transient ischemic attacks), or clinically
             significant ventricular arrhythmias within 6 months prior to randomization

          -  History of stroke within the last 5-years

          -  History of gastrointestinal (GI) bleed requiring transfusion

          -  History of peptic ulcer disease requiring treatment within the last 5-years

          -  History of asthma that is nonsteroidal anti-inflammatory drug (NSAID)-induced or with
             asthma that is classified as 'mild-persistent' or worse (based on symptoms occurring
             more than 2 days per week)

          -  Uncontrolled hypertension

          -  Gastrointestinal disorder affecting absorption

          -  Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)

          -  Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg
             prednisone/ prednisolone once daily

          -  Any condition that in the opinion of the investigator, would preclude participation in
             this study

          -  Child Pugh class B &amp; C

          -  Pre-existing viral hepatitis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schweizer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02849990/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Neoadjuvant Chemotherapy)</title>
          <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Neoadjuvant Chemotherapy)</title>
          <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="51" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="5.6" upper_limit="159.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Gleason score</title>
          <description>Gleason score is a pathological assessment based on the architecture of the prostate gland, with Gleason score 1 indicating well differentiated tumors and a score of 5 being the least differentiated. The total Gleason score is the summation of the two most prevalent differentiation patterns observed. Therefore the lowest possible total Gleason score is 2 and the highest is 10. High total Gleason score correlates with poor clinical outcomes.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate as Assessed From Prostatectomy Specimens Following Neoadjuvant Treatment</title>
        <description>Pathologic complete response is defined as no evidence of cancer on fully submitted prostatectomy specimens using standard surgical pathology assessments (i.e. H&amp;E assessment will be used for the purpose of defining pathologic complete response per protocol) at 3 months.</description>
        <time_frame>At 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy)</title>
            <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate as Assessed From Prostatectomy Specimens Following Neoadjuvant Treatment</title>
          <description>Pathologic complete response is defined as no evidence of cancer on fully submitted prostatectomy specimens using standard surgical pathology assessments (i.e. H&amp;E assessment will be used for the purpose of defining pathologic complete response per protocol) at 3 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apoptotic Index (i.e. Percentage of Tumor Cells Undergoing Apoptosis)</title>
        <description>Will be determined by cleaved caspase-3 immunohistochemistry.</description>
        <time_frame>At 3 months</time_frame>
        <population>Due to limited post-treatment tumor tissue, assessment of apoptotic index is not feasible.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy)</title>
            <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Apoptotic Index (i.e. Percentage of Tumor Cells Undergoing Apoptosis)</title>
          <description>Will be determined by cleaved caspase-3 immunohistochemistry.</description>
          <population>Due to limited post-treatment tumor tissue, assessment of apoptotic index is not feasible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Negative Margin After 3 Months of Treatment</title>
        <description>The absence of tumor cells at the prostate margin will be assessed using standard pathological practices on prostatectomy specimens (i.e. after 3 months of treatment).</description>
        <time_frame>At 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy)</title>
            <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Negative Margin After 3 Months of Treatment</title>
          <description>The absence of tumor cells at the prostate margin will be assessed using standard pathological practices on prostatectomy specimens (i.e. after 3 months of treatment).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative margins</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive margins</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Will be estimated using Kaplan-Meier methods and 95% CI will be estimated using Greenwood's formula.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Near Pathologic Complete Response After 3 Months of Treatment</title>
        <description>The near pathologic complete response will be defined as =&lt; 5 mm of residual tumor as assessed on prostatectomy specimens after 3 months of treatment.</description>
        <time_frame>At 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy)</title>
            <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Near Pathologic Complete Response After 3 Months of Treatment</title>
          <description>The near pathologic complete response will be defined as =&lt; 5 mm of residual tumor as assessed on prostatectomy specimens after 3 months of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With no Nodal Metastases After 3 Months of Treatment.</title>
        <description>The presence of tumor cells within surgically excised lymph nodes will be assessed after 3 months of treament.</description>
        <time_frame>At 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy)</title>
            <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With no Nodal Metastases After 3 Months of Treatment.</title>
          <description>The presence of tumor cells within surgically excised lymph nodes will be assessed after 3 months of treament.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No nodal metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nodal metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Pathologic T3 Disease After 3 Months of Treatment.</title>
        <description>The presence of T3 disease (e.g. extraprostatic tumor not invading adjacent structures) will be determine from the prostatectomy specimen after 3 months of treament.</description>
        <time_frame>At 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy)</title>
            <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Pathologic T3 Disease After 3 Months of Treatment.</title>
          <description>The presence of T3 disease (e.g. extraprostatic tumor not invading adjacent structures) will be determine from the prostatectomy specimen after 3 months of treament.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Biochemical (i.e. Prostate-specific Antigen) Progression-free Survival (PFS) Estimate</title>
        <description>Prostate-specific antigen progression (i.e. biochemical failure) will be defined per the American Urological Association guidelines (i.e. confirmed prostate-specific antigen post-radical prostatectomy &gt;= 0.2 ng/mL). Will be estimated using Kaplan-Meier methods and 95% CI will be estimated using Greenwood's formula.</description>
        <time_frame>At 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Men Who Receive Adjuvant Radiation Therapy</title>
        <description>Patients that received radiation following prostatetomy</description>
        <time_frame>Up to 1 year post prostatectomy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Neoadjuvant Chemotherapy)</title>
            <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Men Who Receive Adjuvant Radiation Therapy</title>
          <description>Patients that received radiation following prostatetomy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For 30 days from the last dose of study drugs.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Neoadjuvant Chemotherapy)</title>
          <description>Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
Abiraterone Acetate: Given PO
Apalutamide: Given PO
Degarelix: Given SC
Indomethacin: Given PO
Laboratory Biomarker Analysis: Correlative study
Prednisone: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mood change</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive Changes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Balance Problem</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Schweizer</name_or_title>
      <organization>University of Washington</organization>
      <phone>2066066252</phone>
      <email>schweize@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

